Du Cheng

TL;DR: The prospects for siRNA to enable a massive reduction in development time for new targeted therapeutic agents are illustrated and a clinical investigation is warranted into siRNA-mediated anti-SARS efficacy.

TL;DR: The first example of a highly packed interlayer-crosslinked micelle (HP-ICM) with reduction and pH dual sensitivity, which comprises a polyethylene glycol (PEG) corona to stabilize the particles, a highly compressed pH-sensitive partially hydrated core to load anticancer drugs, and a disulfide-cross linked interlayer to tie up the core against expansion at neutral pH is described.

TL;DR: Folic acid was employed to potentiate the gene and siRNA delivery to folate receptor (FR)-enriched tumors, which resulted in improved therapeutic effect both in vitro and in vivo and multifunctional nanocarriers combining imaging function with drug delivery are emerging as the next generation of nanomedicines.

TL;DR: It is demonstrated that co-loading siRNA and small molecular drug in a multifunctional hierarchical nano-assembly enabled simultaneously delivering si RNA and drug into the same cancer cells, yielding synergistic effect of RNA interference and chemotherapy in cancer.

TL;DR: It is demonstrated that P-HNPs delivering Cas9 plasmid/sgRNA targeting the polo-like kinase 1 (Plk1) gene achieved 35% gene deletion in HeLa tumor tissue to reduce the Plk1 protein level by 66.7%, thereby suppressing the tumor growth by >71% and prolonging the animal survival rate to 60% within 60 days.